✦ LIBER ✦

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies

✍ Scribed by Albert C. Chen, Ilenia Migliaccio, Mothaffar Rimawi, Sara Lopez-Tarruella, Chad J. Creighton, Suleiman Massarweh, Catherine Huang, Yen-Chao Wang, Surinder K. Batra, M. Carolina Gutierrez, C. Kent Osborne, Rachel Schiff

Book ID: 113062492
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 1009 KB
Volume: 134
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-012-2082-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The role of HER2 in early breast cancer

The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies

✍ Jaclyn A. Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagat 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 297 KB

Role of Endocrine Responsiveness and HER

Role of Endocrine Responsiveness and HER2/neu Overexpression in Inflammatory Breast Cancer Treated with Multimodality Preoperative Therapy

✍ Claudia D’Alessandro; Silvia Dellapasqua; Laura Orlando; Luigi Santoro; Patrick 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

Shorter survival-times following adjuvan

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor

✍ B. Linderholm; J. Bergqvist; H. Hellborg; U. Johansson; M. Linderholm; E. von Sc 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 455 KB

Phase II study of capecitabine and trast

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes

✍ Takanori Ishida; Takayoshi Kiba; Motohiro Takeda; Kotone Matsuyama; Satoshi Tera 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 367 KB

A randomized and open-label trial evalua

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer

✍ Stephen R. D. Johnston, Henry Gómez, Salomon M. Stemmer, Maria Richie, Michael D 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 436 KB

Comprehensive immunohistochemical analys

Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest™ (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH)

✍ Doris Mayr; Sibylle Heim; Cedric Werhan; Evelyn Zeindl-Eberhart; Thomas Kirchner 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 463 KB